The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their ...

UCB was a new entrant among the top 20 biopharmaceutical companies, doubling its market capitalisation from $16.9bn in 2023 to $38.7bn in 2024. Source: GlobalData, Pharma Intelligence Center; Stock ...

Will competition from China put pressure on young U.S. drugmakers? The answers will shape the industry’s fortunes this year, as BioPharma Dive details in the stories below. Read on for a look at ...

and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company dedicated to accelerating the global development of ...

Argo Blockchain CEO Thomas Chippas has stepped down from both his CEO role and board directorship after 14 months of service. His compensation package, which included up to 2.85 million units, was ...

Will 2025 herald a sudden turnaround for biopharma? Unlikely, but continued recovery is likely with some strong growth in therapy areas including cancer, diabetes and – inevitably – obesity. Four of ...

Tanvex BioPharma, Inc. ("Tanvex"), a contract development and manufacturing organization (CDMO) for biologics and a biosimilars products company, is pleased to announce the successful completion ...

Following the strange year for the biopharma industry that was 2024, insiders and analysts alike are waiting expectantly to see how trends in layoffs, drug shortages, clinical trials and more play ...

SAN FRANCISCO — The J.P. Morgan Healthcare Conference isn’t just a venue for companies in the industry to outline their plans for the year or tamp down questions about their finances.

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea for the slow, healthy recovery of the industry at large. The J.P. Morgan ...